President Donald Trump has warned a group of major U.S. drugmakers that his administration is set to impose tariffs on pharmaceutical goods, and they should start moving their manufacturing businesses ...

FibroGen (NASDAQ:FGEN – Get Free Report) and Roche (OTCMKTS:RHHBY – Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the ...

Aurinia can still see growth in product revenues from Lupkynis and has a chance to show that AUR200 has some value in 2025.

Pfizer’s decision to halt further marketing of Beqvez is further sign of the sparse patient interest in gene therapies for the bleeding condition.

Millie, a modern maternity clinic, secured $12 million in Series A funding led by existing investors RH Capital, TMV, ...

Ionis relies on upfront payments and licensing fees from partners, as well as Spinraza royalties, to drive revenue today, but its rapidly advancing portfolio should help diversify revenue. 2025 is ...

During a live event, Alexander I. Spira, MD, PhD, and participants NGS testing practices and the rationale behind their ...

Popular weight-loss therapies like Novo Nordisk's Wegovy and Eli Lilly's Zepbound result in both fat and muscle loss.

COUR Pharmaceuticals has been around a while, but not until last year did the company solidify behind its ultimate mission ...